Nausea and Vomiting

184

Pipeline Programs↗

28

Active Trials↗

55

Companies Involved↗

Nausea and vomiting is a highly competitive landscape with 184 programs across 55 companies. The most active players are Changchun GeneScience Pharmaceutical Co., Ltd., Kyowa Kirin Pharmaceutical Development Ltd, Fujian Shengdi Pharmaceutical Co., Ltd.. 42 therapies are approved with 37 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

34/100

Mech. Concentration

18/100

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Changchun GeneScience Pharmaceutical Co., Ltd.

3 programs

Kyowa Kirin Pharmaceutical Development Ltd

1 program

Fujian Shengdi Pharmaceutical Co., Ltd.

2 programs

Xiamen LP Pharmaceutical Co., Ltd

2 programs

Eli Lilly

2 programs

Vanda Pharmaceuticals

1 program

Pipeline

Programs by Phase

Preclinical60

Ramosetron

Astellas

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Cyclophosphamide

Baxter Healthcare Corporation

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 15

Mirtazapine

Organon and Co

Granisetron IV

Kyowa Kirin Pharmaceutical Development Ltd

Cannabidiol Oil

West Virginia University

Heptaflurane

Mengchang Yang

Cyclophenol

Mengchang Yang

Phase 240

Nabilone

Bausch Health Americas, Inc.

Amisulpride

Acacia Pharma Ltd

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Systemic Chemotherapy

Sun Yat-sen University

Phase 337

Carboplatin

Avyxa

Nab-Paclitaxel

Bristol-Myers Squibb

Gemcitabine

Johnson & Johnson

Thalidomide

Bristol-Myers Squibb

Gabapentin

Viatris Specialty LLC

Approved42

Metoclopramide

Istituto Clinico Humanitas

Olanzapine

MODAG GmbH

Propofol

Fresenius Kabi Oncology Ltd.

Ondansetron

Novartis

Ketamine

Aultman Health Foundation

Analysis

Trial Status

316

clinical trials

Completed209 · 66%

Unknown status50 · 16%

Terminated22 · 7%

Recruiting16 · 5%

Not yet recruiting12 · 4%

Withdrawn6 · 2%

Other1 · 0%

Clinical Trials

Trial Activity

316 trials

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

Recruiting·MMontefiore Medical Center·Phase 2/3·NCT06382012·250 enrolled

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Recruiting·—·Phase 3·NCT07208305·222 enrolled

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Recruiting·—·N/A·NCT06080880·98 enrolled

A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population

Recruiting·—·Phase 3·NCT06585540·100 enrolled

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

Recruiting·DDuchesnay Inc.·Phase 3·NCT05289557·274 enrolled

Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone

Recruiting·MMurdoch Childrens Research Institute·Phase 4·NCT06186141·690 enrolled

Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study

Recruiting·IInternational University of Health and Welfare·Phase 4·NCT07038551·120 enrolled

An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and Vomiting

Recruiting·—·Phase 4·NCT06359535·200 enrolled

The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study

Recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT06417567·50 enrolled

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

Recruiting·—·Phase 3·NCT07248280·260 enrolled

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Recruiting·FFudan University·Phase 3·NCT06017284·100 enrolled

Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery

Recruiting·—·N/A·NCT07086118·210 enrolled

Oliceridine on Postoperative Nausea and Vomiting in Gynecological Laparoscopic Surgery

Recruiting·—·Phase 4·NCT07026162·96 enrolled

Ginger to Prevent Nausea and Vomiting After Laparoscopic Cholecystectomy

Recruiting·UUniversity Tunis El Manar·Phase 4·NCT07190495·102 enrolled

Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery

Recruiting·IIWK Health Centre·Phase 2·NCT06357234·100 enrolled

Page 1 of 22

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)